Noninvasive prenatal testing (NIPT), using massively parallel sequencing of plasma cell-free DNA (cfDNA), has been adopted worldwide for prenatal screening of common fetal aneuploidies 1 . It is based on the analysis of fetal cfDNA fragments, derived from the placenta and freely circulating in the maternal bloodstream. Two basic sequencing approaches are currently in use to analyze circulating fetal cfDNA, namely, random (whole-genome) and targeted sequencing, being outlined in Bianchi and Chiu 1 . In the genome-wide method, chromosomal ratios are calculated based on the number of sequencing reads of the chromosome of interest (eg, chromosome 21 in the case of Down syndrome) relative to the reads of a reference chromosome in a set of normal (diploid) samples. From these ratios, one z-score per chromosome is calculated to determine fetal aneuploidy. A z-score of three is commonly used as a risk threshold above which a trisomy might be suspected. Because the fraction of placenta-derived "fetal" cfDNA exists against a high background of maternal plasma cfDNA, NIPT profiling not only examines fetal but also maternal cfDNA, implying that maternal chromosomal abnormalities can be detected as well 2 .
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Since the introduction of NIPT in prenatal diagnostics, incidental findings of an occult maternal malignancy following a "false-positive" NIPT test have been reported repeatedly. Common cancer types encountered in pregnancy (such as breast cancer, lymphoma, and leukemia) and also other cancers (like ovarian cancer, multiple myeloma, digestive cancers, malignant melanoma, or sarcomas) and benign tumors (uterine leiomyomas) have been accidentally identified upon aberrant NIPT testing (previous work 3-10 and unpublished results).
From these cases, it is now appreciated that the presence of tumorderived cfDNA can skew the NIPT profile and confound its interpretation. Three particular scenarios might be encountered. Firstly, when the observed imbalances are incompatible with fetal development, a maternal malignancy might be invoked. In a second scenario, where such imbalances are compatible with fetal development, a false positive prenatal diagnosis could be made. 10 . This is illustrated in Table 1, representing NIPT data from a series of 26 pregnant cases that had a known diagnosis of breast cancer (n = 24), colon cancer (n = 1), or lymphoma (n = 1), prior to participating to a research study in which genome-wide NIPT testing in this cancer-in-pregnancy setting was evaluated. In six out of the 26 cases, an aberrant NIPT output with chromosome-wide z-scores higher than three for chromosomes 21, 18, and/or 13 was observed, suggesting a fetal trisomy for (one of) the respective chromosomes. However, upon low-pass sequencing of tumor biopsy specimens of these women, it was clear that the
observed gains of chromosomes 21, 18, and 13 in cfDNA were derived from tumor DNA. This resulted in false positive scores of 15.4%, 15.4%, and 19.2% for trisomy 21, 18, and 13, respectively, in this study group of pregnant cancer patients. Figure 1 visualizes the NIPT output for one of these six cases, i.e. a woman that was diagnosed with a stage II, triple negative breast cancer when being 8 weeks pregnant. When limiting the analyses to the commonly tested fetal chromosomes, z-scores higher than 3 were observed for chromosomes 21, 18, and 13. A genome-wide inspection however showed the presence of chromosomal imbalances in almost all 22 autosomes.
Upon comparison with the copy number profile of matched tumor biopsy DNA, the (sub)chromosomal CNAs and aneuploidies observed in cfDNA were shown to originate from tumor DNA. This woman gave birth to a baby boy with a normal neonatal outcome. Finally, also an NIPT outcome with an apparently normal result (for the investigated fetal chromosomes) cannot accurately be applied to assess the fetal chromosomal constitution as (a) z-scores of particular fetal chromosomes or chromosomal fragments might be skewed due to excessive presentation of highly amplified tumoral chromosomes or chromosome arms or (b) chromosomal amplifications and deletions in the fetal and tumoral cfDNA may cancel each other out resulting in a neutral zscore for a particular chromosome. In our study cohort of pregnant cancer patients, five women had a negative z-score (z ≤ −3) for chromosomes 21, 18, 13 or a combination of these chromosomes. Except for one case, all observed aneuploidies in cfDNA were shown to reflect true monosomies in the tumor DNA ( Table 1 ). All these five women gave birth to a child with no congenital malformations. If, however, one of these children would have been affected by a true fetal trisomy (characterized by a z-score ≥ 3), then the monosomies in the tumor DNA would have neutralized the final z-score for the respective chromosomes, resulting in a false negative NIPT output.
The theoretical risk of such a false negative NIPT score in our patient cohort ranged from 7.7% to 15.4% for chromosomes 21, 18, and 13 (Table 1) What's already known about this topic?
• Incidental diagnoses of an occult maternal malignancy have been reported upon aberrant routine noninvasive prenatal testing (NIPT).
• The presence of tumor-derived cell-free DNA in the maternal circulation can skew the NIPT profile.
What does this study add? 
